{
    "guideline_identifier": "PIIS092375342204193X.txt",
    "cancer_focus": {
        "primary_cancer": "Breast Cancer",
        "related_syndrome_or_condition": "Hereditary Breast and Ovarian Cancer Syndrome"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Breast cancer risk",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "BRCA1 carriers",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Breast MRI every 6 months starting at age 30 (or 5 years before youngest affected relative)",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level A"
                },
                {
                    "clinical_context": "BRCA2/PALB2 carriers",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Annual breast MRI starting at age 30 (or 5 years before youngest affected relative)",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "PALB2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level A"
                },
                {
                    "clinical_context": "Carriers â‰¥40 years when MRI unavailable",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Supplemental mammography/ultrasound",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                },
                {
                    "clinical_context": "High-risk gene carriers (BRCA1/2, PALB2, TP53, PTEN, STK11, CDH1)",
                    "recommendation_type": "Risk-reducing surgery",
                    "recommendation_content": "Risk-reducing mastectomy (RRM)",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "PALB2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "TP53",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "PTEN",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "STK11",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "CDH1",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level B"
                },
                {
                    "clinical_context": "All carriers considering RRM",
                    "recommendation_type": "Risk-reducing surgery",
                    "recommendation_content": "Nipple-sparing mastectomy (NSM) is acceptable",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                },
                {
                    "clinical_context": "Premenopausal carriers",
                    "recommendation_type": "Pharmacoprevention",
                    "recommendation_content": "Tamoxifen reduces breast cancer risk by 30-60%",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                },
                {
                    "clinical_context": "Postmenopausal carriers",
                    "recommendation_type": "Pharmacoprevention",
                    "recommendation_content": "Aromatase inhibitors reduce breast cancer risk by 30-60%",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                },
                {
                    "clinical_context": "Male BRCA2 carriers with gynecomastia/Klinefelter",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Annual mammography/ultrasound",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                }
            ]
        },
        {
            "staging_criteria": "Ovarian cancer risk",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Pre-RRBSO carriers",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Transvaginal ultrasound + serum CA-125 every 6 months starting at RRBSO-recommended age",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                },
                {
                    "clinical_context": "BRCA1 carriers",
                    "recommendation_type": "Risk-reducing surgery",
                    "recommendation_content": "RRBSO at 35-40 years",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level B"
                },
                {
                    "clinical_context": "BRCA2 carriers",
                    "recommendation_type": "Risk-reducing surgery",
                    "recommendation_content": "RRBSO at 40-45 years",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level B"
                },
                {
                    "clinical_context": "All RRBSO procedures",
                    "recommendation_type": "Risk-reducing surgery",
                    "recommendation_content": "Pathology examination with SEE-FIM protocol",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "Any HBOC gene",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline testing for clinically validated HBOC genes"
                        }
                    ],
                    "esmo_evidence_level": "Level A"
                }
            ]
        },
        {
            "staging_criteria": "Prostate cancer risk",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "BRCA2 carriers",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Annual PSA screening starting at age 40",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level B"
                },
                {
                    "clinical_context": "ATM carriers",
                    "recommendation_type": "Screening",
                    "recommendation_content": "Annual PSA screening starting at age 40",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "ATM",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                }
            ]
        },
        {
            "staging_criteria": "Pancreatic cancer risk",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "BRCA1/2, ATM, PALB2 carriers with family history",
                    "recommendation_type": "Screening",
                    "recommendation_content": "MRI/endoscopic ultrasound from age 50 (or 5-10 years before affected relative)",
                    "treatment_line": "Prevention",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "BRCA2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "ATM",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        },
                        {
                            "name": "PALB2",
                            "status": "Pathogenic variant",
                            "testing_guidance": "Germline genetic testing via multigene panels"
                        }
                    ],
                    "esmo_evidence_level": "Level C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Germline pathogenic variants predict cancer risk and guide risk-reducing interventions including enhanced screening, prophylactic surgeries, and pharmacoprevention"
    }
}